Saturday 17 October 2026
Export VTGN’s income statement to Excel — free account
VistaGen Therapeutics, Inc.
VTGN Healthcare Biotechnology
VistaGen Therapeutics, Inc.’s revenue for fiscal 2026 (year ended March 2026) was $1.3 million, up 161.1% from fiscal 2025. In the quarter to June 2026, revenue grew 504.9%, EPS grew 36.2% and free cash flow grew 22.2%, each against the same quarter a year earlier.
0.20
0.01
−4.76%
Follow VTGN
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
3 | 3 | 3 | 2 |
+8 more TTM periods Free account |
| (166.46%) | (131.59%) | (101.55%) | (78.13%) | ||
| (129.22%) | (104.86%) | (85.21%) | (67.86%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(287.83%) | (201.55%) | (133.57%) | (94.57%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.45) | (1.75) | (1.43) | (1.49) | |
Free Cash Flow |
(62.30) | (66.59) | (60.54) | (53.16) | |
Capital Expenditures |
— | (0.15) | (0.24) | (0.21) | |
| Other line items | |||||
Cash ROIC |
(110.83%) | (82.28%) | (53.72%) | (37.04%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
2,167.21% | 4,332.07% | 6,585.19% | 6,810.68% | |
Selling, General and Administrative Expense of Revenue |
718.47% | 1,451.62% | 2,362.66% | 2,370.04% | |
Share Based Compensation of Revenue |
162.81% | 314.97% | 515.32% | 562.41% | |
Operating CF/Net income |
0.92 | 0.95 | 0.90 | 0.85 | |
Depreciation/Fixed assets |
(0.90) | (0.81) | (0.74) | (0.64) | |
Capex/Depreciation |
0.00 | 0.44 | 0.68 | 0.65 | |
Revenue per Share |
0.06 | 0.03 | 0.02 | 0.02 | |
Operating CF per Share |
(1.45) | (1.74) | (1.43) | (1.48) | |
Capex per Share |
0.00 | 0.00 | (0.01) | (0.01) | |
Capex to Sales |
0.00 | 0.12 | 0.30 | 0.30 |
Columns are period end dates